\-\ Texto\\:\\ \ \(0\)\
\-\ n\\/a\ \(127\)\
\-\ patient\\ will\\ require\\ followup\\ with\\ his\\ pcm\\ for\\ cr\\ and\\ ct\\ as\\ indicated\\.\ \(0\)\
\-\ pleural\\ calcifications\\ at\\ bilateral\\ post\\/lat\\ and\\ base\\ predominately\\ at\\ middle\\ and\\ lower\\ chest\\.\ \(0\)\
\-\ holly\\ leaf\\ appearance\\.\ \(0\)\
\-\ asbestos\\-related\\ pleural\\ disease\ \(1\)\
\-\ sequella\\ of\\ prior\\ hemothorax\\,\\ empyema\\,\\ surgery\ \(0\)\
\-\ tuberculosis\ \(73\)\
\-\ asbestos\\-related\\ pleural\\ disease\ \(1\)\
\-\ 60\\ y\\.o\\.\\ man\\ with\\ rib\\ contusion\\ \\-\\ r\\/o\\ fracture\\.\ \(1\)\
\-\ focal\\ pleural\\ plaques\\ are\\ the\\ most\\ common\\ manifestation\\ of\\ asbestos\\ exposure\\ and\\ develop\\ 20\\-30\\ years\\ after\\ exposure\\.\\ \\ most\\ often\\ focal\\ interrupted\\ areas\\ of\\ plural\\ thickening\\ located\\ in\\ the\\ posterolateral\\ middle\\ and\\ lower\\ chest\\ bilaterally\\ and\\ represent\\ hyalinized\\ collagen\\ in\\ submesothelial\\ layer\\ of\\ parietal\\ pleura\\.\\ the\\ mediastinal\\ pleural\\ surface\\ and\\ costophrenic\\ sulci\\ are\\ characteristically\\ spared\\.\\ \\ \ \(0\)\
\-\ diffuse\\ pleural\\ thickening\\ is\\ less\\ common\\ than\\ focal\\ plaques\\,\\ are\\ associated\\ with\\ round\\ atelectasis\\,\\ and\\ may\\ cause\\ respiratory\\ symptoms\\.\\ \\ \ \(0\)\
\-\ pleural\\ calcifications\\,\\ as\\ in\\ this\\ case\\,\\ in\\ the\\ absence\\ of\\ hemothorax\\,\\ empyema\\,\\ tuberculosis\\ or\\ previous\\ surgery\\ is\\ pathognomonic\\.\\ \\ this\\ requires\\ greater\\ than\\ 20\\ years\\ to\\ develop\\.\\ \\ \ \(0\)\
\-\ an\\ early\\ sign\\ of\\ asbestos\\-related\\ pleural\\ disease\\ are\\ pleural\\ effusions\\ but\\ as\\ with\\ pleural\\ calcifications\\ other\\ causes\\ must\\ be\\ excluded\\.\\ \\ these\\ include\\ malignant\\ mesothelioma\\,\\ bronchogenic\\ carcinoma\\ and\\ tuberculosis\\.\\ \\ \ \(0\)\
\-\ malignancy\\ in\\ asbestos\\-related\\ disease\ \(0\)\
\-\ 7000x\\ increased\\ incidence\\ of\\ mesothelioma\\;\\ however\\,\\ this\\ equals\\ a\\ 10\\ \\%\\ lifetime\\ risk\\,\\ \\>30yrs\\ after\\ exposure\\.\ \(1\)\
\-\ other\\ associated\\ increase\\ risks\\ include\\ 7x\\ increase\\ in\\ bronchogenic\\ carcinoma\\ and\\ 3x\\ increase\\ in\\ gastrointestinal\\ neoplasia\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ pleural\\:\\ 0\\.13655762134458008\ \(0\)\
\-\ asbestos\\-related\\:\\ 0\\.13370158425360582\ \(0\)\
\-\ exposure\\:\\ 0\\.05488976014196885\ \(0\)\
\-\ tuberculosis\\:\\ 0\\.050254151797570965\ \(0\)\
\-\ hemothorax\\:\\ 0\\.04484133822205781\ \(0\)\
\-\ increase\\:\\ 0\\.044251972927307544\ \(0\)\
\-\ mesothelioma\\:\\ 0\\.04403113186145491\ \(0\)\
\-\ empyema\\:\\ 0\\.042836218200183324\ \(0\)\
\-\ plaques\\:\\ 0\\.039279565071044846\ \(0\)\
\-\ calcifications\\:\\ 0\\.03922424388435496\ \(0\)\
\-\ bronchogenic\\:\\ 0\\.03713130313384633\ \(0\)\
\-\ post\\/lat\\:\\ 0\\.03627785359656995\ \(0\)\
\-\ submesothelial\\:\\ 0\\.03627785359656995\ \(0\)\
\-\ 7000x\\:\\ 0\\.03627785359656995\ \(0\)\
\-\ 30yrs\\:\\ 0\\.03627785359656995\ \(0\)\
\-\ 7x\\:\\ 0\\.03627785359656995\ \(0\)\
\-\ develop\\:\\ 0\\.03507523894951406\ \(0\)\
\-\ holly\\:\\ 0\\.033425396063401454\ \(0\)\
\-\ sequella\\:\\ 0\\.03175681537159831\ \(0\)\
\-\ 3x\\:\\ 0\\.03175681537159831\ \(0\)\
\-\ leaf\\:\\ 0\\.030572938530232956\ \(0\)\
\-\ hyalinized\\:\\ 0\\.030572938530232956\ \(0\)\
\-\ focal\\:\\ 0\\.030129550668375332\ \(0\)\
\-\ equals\\:\\ 0\\.029654652310832915\ \(0\)\
\-\ plural\\:\\ 0\\.028269992900869075\ \(0\)\
\-\ interrupted\\:\\ 0\\.027720480997064454\ \(0\)\
\-\ lifetime\\:\\ 0\\.027720480997064454\ \(0\)\
\-\ pcm\\:\\ 0\\.026802194777664417\ \(0\)\
\-\ middle\\:\\ 0\\.02572147300117233\ \(0\)\
\-\ 20\\-30\\:\\ 0\\.024383319613458167\ \(0\)\
\-\ neoplasia\\:\\ 0\\.024383319613458167\ \(0\)\
\-\ characteristically\\:\\ 0\\.024160820760494067\ \(0\)\
\-\ spared\\:\\ 0\\.023949737244495915\ \(0\)\
\-\ thickening\\:\\ 0\\.023840531437805366\ \(0\)\
\-\ asbestos\\:\\ 0\\.023374585218260698\ \(0\)\
\-\ costophrenic\\:\\ 0\\.023031451025095875\ \(0\)\
\-\ disease\\:\\ 0\\.02299156446445604\ \(0\)\
\-\ manifestation\\:\\ 0\\.022714738921655018\ \(0\)\
\-\ risks\\:\\ 0\\.022714738921655018\ \(0\)\
\-\ predominately\\:\\ 0\\.022565077834532075\ \(0\)\
\-\ layer\\:\\ 0\\.02228115655269277\ \(0\)\
\-\ r\\/o\\:\\ 0\\.021646791615132038\ \(0\)\
\-\ pleura\\:\\ 0\\.021201468221550834\ \(0\)\
\-\ cr\\:\\ 0\\.021097279711327417\ \(0\)\
\-\ years\\:\\ 0\\.02065220688904101\ \(0\)\
\-\ sulci\\:\\ 0\\.02009750119852746\ \(0\)\
\-\ collagen\\:\\ 0\\.020017591380185475\ \(0\)\
\-\ posterolateral\\:\\ 0\\.01993920374656122\ \(0\)\
\-\ carcinoma\\:\\ 0\\.019933561070089437\ \(0\)\
\-\ include\\:\\ 0\\.019729658337697836\ \(0\)\
\-\ contusion\\:\\ 0\\.01936067720079501\ \(0\)\
\-\ are\\:\\ 0\\.019174878560158055\ \(0\)\
\-\ gastrointestinal\\:\\ 0\\.019163108397558956\ \(0\)\
\-\ pathognomonic\\:\\ 0\\.019036476057366553\ \(0\)\
\-\ excluded\\:\\ 0\\.019036476057366553\ \(0\)\
\-\ requires\\:\\ 0\\.018678404547121167\ \(0\)\
\-\ than\\:\\ 0\\.01842838563718744\ \(0\)\
\-\ common\\:\\ 0\\.018405491456431253\ \(0\)\
\-\ effusions\\:\\ 0\\.017947206286884735\ \(0\)\
\-\ rib\\:\\ 0\\.017581167249779813\ \(0\)\
\-\ surgery\\:\\ 0\\.017078181599673045\ \(0\)\
\-\ atelectasis\\:\\ 0\\.016897070875120018\ \(0\)\
\-\ chest\\:\\ 0\\.016829045267963118\ \(0\)\
\-\ followup\\:\\ 0\\.01678732500235392\ \(0\)\
\-\ associated\\:\\ 0\\.016596399686483146\ \(0\)\
\-\ most\\:\\ 0\\.016237326269366883\ \(0\)\
\-\ other\\:\\ 0\\.01621101686174855\ \(0\)\
\-\ incidence\\:\\ 0\\.016122134255208177\ \(0\)\
\-\ require\\:\\ 0\\.01609153763591798\ \(0\)\
\-\ must\\:\\ 0\\.016031018510857503\ \(0\)\
\-\ as\\:\\ 0\\.015957746986347256\ \(0\)\
\-\ lower\\:\\ 0\\.01581779480957912\ \(0\)\
\-\ surface\\:\\ 0\\.015523017724474288\ \(0\)\
\-\ represent\\:\\ 0\\.015444129180821118\ \(0\)\
\-\ 60\\:\\ 0\\.015341243163514874\ \(0\)\
\-\ indicated\\:\\ 0\\.015216150664813759\ \(0\)\
\-\ round\\:\\ 0\\.015191582076391931\ \(0\)\
\-\ parietal\\:\\ 0\\.015023590329394999\ \(0\)\
\-\ mediastinal\\:\\ 0\\.014930586905867255\ \(0\)\
\-\ absence\\:\\ 0\\.014620692325356432\ \(0\)\
\-\ respiratory\\:\\ 0\\.01459942495844926\ \(0\)\
\-\ after\\:\\ 0\\.014551450227236236\ \(0\)\
\-\ located\\:\\ 0\\.014474078425590379\ \(0\)\
\-\ base\\:\\ 0\\.013775548489017972\ \(0\)\
\-\ causes\\:\\ 0\\.013689632501274945\ \(0\)\
\-\ previous\\:\\ 0\\.01365576213445801\ \(0\)\
\-\ malignancy\\:\\ 0\\.013588846410705827\ \(0\)\
\-\ greater\\:\\ 0\\.013208709290825108\ \(0\)\
\-\ early\\:\\ 0\\.012860736500586166\ \(0\)\
\-\ n\\/a\\:\\ 0\\.01273747591505797\ \(0\)\
\-\ risk\\:\\ 0\\.01273747591505797\ \(0\)\
\-\ malignant\\:\\ 0\\.012710578915141157\ \(0\)\
\-\ 20\\:\\ 0\\.012644095622045333\ \(0\)\
\-\ \\,\\:\\ 0\\.012254365105720828\ \(0\)\
\-\ sign\\:\\ 0\\.012182907414666959\ \(0\)\
\-\ in\\:\\ 0\\.012139014860007343\ \(0\)\
\-\ less\\:\\ 0\\.011909218124784703\ \(0\)\
\-\ cause\\:\\ 0\\.011898200109267352\ \(0\)\
\-\ this\\:\\ 0\\.011865891522396704\ \(0\)\
\-\ 10\\:\\ 0\\.01185442069278564\ \(0\)\
\-\ areas\\:\\ 0\\.011832704408420028\ \(0\)\
\-\ \\>\\:\\ 0\\.011683816932792447\ \(0\)\
\-\ bilaterally\\:\\ 0\\.01155022731902841\ \(0\)\
\-\ often\\:\\ 0\\.011220055755224908\ \(0\)\
\-\ will\\:\\ 0\\.011001979499502643\ \(0\)\
\-\ diffuse\\:\\ 0\\.010646121071503353\ \(0\)\
\-\ y\\.o\\:\\ 0\\.010149709599122224\ \(0\)\
\-\ his\\:\\ 0\\.01013534579278573\ \(0\)\
\-\ appearance\\:\\ 0\\.010057228710842147\ \(0\)\
\-\ however\\:\\ 0\\.009791638088876833\ \(0\)\
\-\ at\\:\\ 0\\.009528914838120437\ \(0\)\
\-\ fracture\\:\\ 0\\.009271910824167815\ \(0\)\
\-\ these\\:\\ 0\\.009151624246740084\ \(0\)\
\-\ prior\\:\\ 0\\.009029270667499438\ \(0\)\
\-\ symptoms\\:\\ 0\\.00876402253867547\ \(0\)\
\-\ increased\\:\\ 0\\.008602818032097349\ \(0\)\
\-\ bilateral\\:\\ 0\\.008534229338742568\ \(0\)\
\-\ \\;\\:\\ 0\\.008335066619146477\ \(0\)\
\-\ man\\:\\ 0\\.008316591946872426\ \(0\)\
\-\ \\%\\:\\ 0\\.00820296721541567\ \(0\)\
\-\ may\\:\\ 0\\.00771328546871656\ \(0\)\
\-\ case\\:\\ 0\\.007693433880112226\ \(0\)\
\-\ \\-\\:\\ 0\\.007537977196330715\ \(0\)\
\-\ but\\:\\ 0\\.0075000135845001556\ \(0\)\
\-\ and\\:\\ 0\\.007407778013671542\ \(0\)\
\-\ be\\:\\ 0\\.005422867174254853\ \(0\)\
\-\ ct\\:\\ 0\\.00491894507568742\ \(0\)\
\-\ an\\:\\ 0\\.004862818371542099\ \(0\)\
\-\ is\\:\\ 0\\.004627907641026549\ \(0\)\
\-\ or\\:\\ 0\\.004121492794089332\ \(0\)\
\-\ patient\\:\\ 0\\.003525069674553037\ \(0\)\
\-\ of\\:\\ 0\\.0033560765661971976\ \(0\)\
\-\ for\\:\\ 0\\.0030004450561428608\ \(0\)\
\-\ the\\:\\ 0\\.002275708390183141\ \(0\)\
\-\ \\.\\:\\ 0\\.0021913293887250787\ \(0\)\
\-\ with\\:\\ 0\\.0019259946681463333\ \(0\)\
\-\ to\\:\\ 0\\.0017574819277489148\ \(0\)\
\-\ a\\:\\ 0\\.0016320979498707872\ \(0\)\
